Health & Fitness
Health and Fitness
Health and Fitness
Thu, January 29, 2009
Wed, January 28, 2009 Metabasis Therapeutics to Present at the 11th Annual BIO CEO and Investor Conference
SAN DIEGO--([ BUSINESS WIRE ])--Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that Dr. Mark Erion, president, chief executive officer and chief scientific officer, will present at the 11th Annual BIO CEO & Investor Conference at the Waldorf-Astoria in New York City. Dr. Erion is scheduled to present on Monday, February 9 at 2:15pm Eastern Time and is expected to provide an overview of the Company and its product candidates. The Company's presentation will be webcast.
To access the live audio broadcast and the subsequent archived audio recording of the presentation, please log onto the Company's website at [ www.mbasis.com ] under the "Investors" section. The audio recordings will be archived there for 30 days following the live presentation. Please connect to Metabasis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Metabasis ([ www.mbasis.com ]):
Metabasis is a biopharmaceutical company using its proprietary technologies, scientific expertise and unique capabilities for targeting the liver and liver pathways to develop novel therapies to treat metabolic and other diseases. The company has established a broad pipeline of product candidates and advanced research programs targeting large markets with significant unmet needs. Metabasis' core area of focus is on the discovery and development of product candidates to treat metabolic diseases such as hyperlipidemia and diabetes, among others. Although not a core focus of the company, Metabasis has also discovered and is developing product candidates indicated for the treatment of liver diseases such as hepatitis and primary liver cancer, which it now intends to license or sell. All product candidates have been developed internally using proprietary technologies.
Forward-Looking Statements:
Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Metabasis' product pipeline, capabilities and long term goals; the status of ongoing and future partnering activities, including the newly established collaboration with Roche and collaborations being sought for other programs and product candidates; and the impact of the reorganization and reduction in force, including the company's ability to reach milestones and recommend compounds for clinical development notwithstanding the reduction in force. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Metabasis' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress and timing of clinical trials for Metabasis' product candidates; the fact that positive results from preclinical studies and early clinical trials does not necessarily mean later clinical trials will succeed; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing Metabasis' product candidates; serious adverse side effects or inadequate efficacy of, or serious adverse events related to, Metabasis' product candidates or proprietary technologies; the risk that Metabasis will not be able to build more value or retain rights for direct commercialization of its product candidates; Metabasis' dependence on its licensees and collaborators for the clinical development and registration of, as well as information relating to, certain of its product candidates; potential conflicts with collaborators that could delay or prevent the development or commercialization of Metabasis' product candidates; the scope and validity of intellectual property protection for Metabasis' product candidates, proprietary technologies and their uses; competition from other pharmaceutical or biotechnology companies; Metabasis' ability to obtain additional financing to support its operations; Metabasis' ability to generate financing through partnerships; Metabasis' ability to maintain compliance with Nasdaq Global Market continued listing requirements; and other factors discussed in the "Risk Factors" section of Metabasis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Metabasis is providing this information as of this date of this release and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
